Kelly J Atkins1, Sophie C Andrews1,2,3, Trevor T-J Chong1,4,5, Julie C Stout1. 1. School of Psychological Sciences, Turner Institute for Brain and Mental Health Monash University Melbourne Victoria Australia. 2. Neuroscience Research Australia Sydney New South Wales Australia. 3. School of Psychiatry University of New South Wales Sydney New South Wales Australia. 4. Department of Neurology Alfred Health Melbourne Victoria Australia. 5. Department of Clinical Neurosciences St Vincent's Hospital Melbourne Victoria Australia.
Abstract
BACKGROUND: Apathy is a disorder of motivation common to Huntington's disease (HD). Recent conceptual frameworks suggest that apathy is not unitary but consists of discrete subtypes ("dimensions"). Which of the proposed dimensions are preferentially affected in HD, and how these dimensions evolve with disease progression is unknown. OBJECTIVES: The Dimensional Apathy Scale (DAS) separates apathy into Executive, Initiation and Emotional subscales. Using the DAS, we aimed to: 1) Determine the apathy subtypes prevalent in HD; 2) Compare the DAS against a unitary measure of apathy (Apathy Evaluation Scale, AES); 3) Assess the reliability of self- and observer-ratings; and 4) Determine the relationship between the DAS, and disease burden, total functional capacity (TFC) and the AES. METHOD: Fifty pre-manifest, 51 manifest-HD, 87 controls, and 50 HD-observers completed the DAS, AES, and TFC. RESULTS: Manifest-HD participants had the highest levels of apathy across all dimensions (30.4% on Executive subscale, 34.8% on Initiation subscale, and 15.2% on Emotional subscale), relative to pre-manifest and control participants. Self- and observer-ratings on the DAS did not differ. Hierarchical regressions across the entire gene-expanded sample showed that scores on the Initiation subscale correlated with AES scores; higher Executive subscale scores were related to higher disease burden; and Emotional subscale scores with lower total functional capacity. CONCLUSIONS: In this first study of the DAS in HD, manifest-HD participants were more apathetic than pre-manifest and control participants across all apathy subtypes. The DAS may be a useful tool for measuring different aspects of apathy in people with HD.
BACKGROUND: Apathy is a disorder of motivation common to Huntington's disease (HD). Recent conceptual frameworks suggest that apathy is not unitary but consists of discrete subtypes ("dimensions"). Which of the proposed dimensions are preferentially affected in HD, and how these dimensions evolve with disease progression is unknown. OBJECTIVES: The Dimensional Apathy Scale (DAS) separates apathy into Executive, Initiation and Emotional subscales. Using the DAS, we aimed to: 1) Determine the apathy subtypes prevalent in HD; 2) Compare the DAS against a unitary measure of apathy (Apathy Evaluation Scale, AES); 3) Assess the reliability of self- and observer-ratings; and 4) Determine the relationship between the DAS, and disease burden, total functional capacity (TFC) and the AES. METHOD: Fifty pre-manifest, 51 manifest-HD, 87 controls, and 50 HD-observers completed the DAS, AES, and TFC. RESULTS: Manifest-HD participants had the highest levels of apathy across all dimensions (30.4% on Executive subscale, 34.8% on Initiation subscale, and 15.2% on Emotional subscale), relative to pre-manifest and control participants. Self- and observer-ratings on the DAS did not differ. Hierarchical regressions across the entire gene-expanded sample showed that scores on the Initiation subscale correlated with AES scores; higher Executive subscale scores were related to higher disease burden; and Emotional subscale scores with lower total functional capacity. CONCLUSIONS: In this first study of the DAS in HD, manifest-HD participants were more apathetic than pre-manifest and control participants across all apathy subtypes. The DAS may be a useful tool for measuring different aspects of apathy in people with HD.
Authors: P H Robert; S Clairet; M Benoit; J Koutaich; C Bertogliati; O Tible; H Caci; M Borg; P Brocker; P Bedoucha Journal: Int J Geriatr Psychiatry Date: 2002-12 Impact factor: 3.485
Authors: Kevin Duff; Jane S Paulsen; Leigh J Beglinger; Douglas R Langbehn; Julie C Stout Journal: Biol Psychiatry Date: 2007-05-03 Impact factor: 13.382
Authors: Sarah J Tabrizi; Douglas R Langbehn; Blair R Leavitt; Raymund Ac Roos; Alexandra Durr; David Craufurd; Christopher Kennard; Stephen L Hicks; Nick C Fox; Rachael I Scahill; Beth Borowsky; Allan J Tobin; H Diana Rosas; Hans Johnson; Ralf Reilmann; Bernhard Landwehrmeyer; Julie C Stout Journal: Lancet Neurol Date: 2009-07-29 Impact factor: 44.182
Authors: Tiago A Mestre; Erik van Duijn; Aileen M Davis; Anne-Catherine Bachoud-Lévi; Monica Busse; Karen E Anderson; Joaquim J Ferreira; Philipp Mahlknecht; Vitor Tumas; Cristina Sampaio; Chris G Goetz; Esther Cubo; Glenn T Stebbins; Pablo Martinez-Martin Journal: Mov Disord Date: 2016-10 Impact factor: 10.338
Authors: Mindaugas Jurgelis; Wei Binh Chong; Kelly J Atkins; Patrick S Cooper; James P Coxon; Trevor T-J Chong Journal: Sci Rep Date: 2021-11-15 Impact factor: 4.379